Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Nov;124(11):4759-72.
doi: 10.1172/JCI70102. Epub 2014 Oct 20.

Tachycardia-induced silencing of subcellular Ca2+ signaling in atrial myocytes

Tachycardia-induced silencing of subcellular Ca2+ signaling in atrial myocytes

Maura Greiser et al. J Clin Invest. 2014 Nov.

Abstract

Atrial fibrillation (AF) is characterized by sustained high atrial activation rates and arrhythmogenic cellular Ca2+ signaling instability; however, it is not clear how a high atrial rate and Ca2+ instability may be related. Here, we characterized subcellular Ca2+ signaling after 5 days of high atrial rates in a rabbit model. While some changes were similar to those in persistent AF, we identified a distinct pattern of stabilized subcellular Ca2+ signaling. Ca2+ sparks, arrhythmogenic Ca2+ waves, sarcoplasmic reticulum (SR) Ca2+ leak, and SR Ca2+ content were largely unaltered. Based on computational analysis, these findings were consistent with a higher Ca2+ leak due to PKA-dependent phosphorylation of SR Ca2+ channels (RyR2s), fewer RyR2s, and smaller RyR2 clusters in the SR. We determined that less Ca2+ release per [Ca2+]i transient, increased Ca2+ buffering strength, shortened action potentials, and reduced L-type Ca2+ current contribute to a stunning reduction of intracellular Na+ concentration following rapid atrial pacing. In both patients with AF and in our rabbit model, this silencing led to failed propagation of the [Ca2+]i signal to the myocyte center. We conclude that sustained high atrial rates alone silence Ca2+ signaling and do not produce Ca2+ signaling instability, consistent with an adaptive molecular and cellular response to atrial tachycardia.

PubMed Disclaimer

Figures

Figure 10
Figure 10. Ca2+ signaling silencing in human AF.
(A) Representative transverse confocal linescan and derived local CaTs from a CTL cell (patient in sinus rhythm) during steady-state field stimulation (0.5 Hz) showing similar amplitudes of ss and cc CaTs. (B) As in A for an AF cell showing the significantly blunted cc CaT. (C) Reduced cc but preserved ss CaT amplitude in human AF cells (CTL: n = 39 cells, 9 patients; AF: n = 23 cells, 10 patients). **P < 0.01.
Figure 9
Figure 9. Ca2+ sparks and Ca2+ waves.
(A) Ca2+ spark frequency, amplitude, mass, and Ca2+ spark–mediated Ca2+ leak in a CTL cell in ss (CTL: n = 250, 21 cells, 5 animals; RAP: n = 210, 19 cells, 5 animals) and cc (CTL: n = 80, 21 cells, 5 animals; RAP: n = 90, 19 cells, 5 animals) domains. (B) As in A for RAP cells. ss (n = 210, 19 cells, 5 animals) and cc (n = 90, 19 cells, 5 animals) regions. (C) Ca2+ wave inducibility (CTL: n = 33 cells, 6 animals; RAP: n = 34 cells, 6 animals). (D) Ca2+ wave frequency at baseline and after stimulation with 1 μmol/l isoproterenol in the same cell (CTL: n = 25 cells, 5 animals; RAP: n = 22 cells, 5 animals).
Figure 8
Figure 8. RyR2 in atrial myocytes.
(A) Confocal immunofluorescence image of RyR2 clusters in a CTL cell. (B) As in A, but with an RAP cell. Both panels show transverse spacing of RyR2 clusters. Enlarged panels show the region of interest (ROI) that was used to obtain the transverse RyR2 cluster distance. Below are the intensity profiles along each ROI. §, denotes the peaks of intensity, and their distance is measured as the spacing between the RyR2 clusters. Representative histograms of transverse RyR2 cluster spacing from 1 animal (10 cells). (C) Percentiles and heterogeneity index (p95-p5/p50) for CTL and RAP cells (CTL: 408 ROI, n = 51 cells, n = 8; RAP: 420 ROIs, n = 60 cells, n = 8). (D) Western blot analyses showing changes in total RyR2 protein expression and phosphorylation in RAP cells (CTL: n = 18; RAP: n = 15). n = number of animals. *P < 0.05.
Figure 7
Figure 7. Fast [Ca2+] buffering components.
(A) Pro-Q Diamond staining (ProQ) to evaluate phosphorylation of myofilament proteins and SYPRO Ruby (SYPRO) to analyze total protein expression. cMyBP-C, cardiac myosin–binding protein C; TnT and TnI, cardiac TnT and TnI; MLC2, myosin light chain 2. (CTL: n = 17; RAP: n = 14.) (B) TnI protein expression. (C) Reduced TnI phosphorylation at Ser23/24 (CTL: n = 17; RAP; n = 14). (D) Increased calmodulin (CaM) and unchanged TnC protein expression levels (E) in RAP (relative to CTL and normalized to GADPH; CTL: n = 15; RAP: n = 11). *P < 0.05.
Figure 6
Figure 6. Intracellular Ca2+ buffering strength.
Confocal linescans and derived local CaTs of a CTL cell (2 Hz) at baseline (A) and after application of 1 μmol of the Ca2+ chelator BAPTA-AM (n = 13 cells, 4 animals) (B). Similar ss and cc CaT amplitudes in CTL cells during steady-state stimulation (2 Hz) (A) and reduced cc CaT amplitude after treatment with 1 μmol/l BAPTA-AM (B). (C) Left panel: Example of intracellular Ca2+ buffering strength in an RAP cell and a CTL cell plotting the reverse ∫INCX (total Ca2+) and the falling phase of the whole-cell CaT (epifluorescence, fluo-3; free Ca2+) that were simultaneously recorded during fast application of caffeine (10 mmol/l). Right panel: Slopes of intracellular Ca2+ buffering strength in CTL versus RAP cells (CTL: n = 15 cells, 5 animals; RAP: n = 13 cells, 6 animals). (D) Confocal linescans of a CTL cell at baseline (left) and after addition of the Ca2+ sensitizer EMD (3 μmol/l) (n = 12 cells, 4 animals). *P 0.05; **P 0.01.
Figure 5
Figure 5. Altered Na+ homeostasis in RAP.
(A and B) Representative ratiometric measurements of [Na+]i in a CTL cell and an RAP cell with in situ calibration. (C) [Na]i at rest and during stimulation. **P 0.01; ***P 0.001. (D) Δ[Na]i in stimulated myocytes (CTL: 12 cells, 10 animals; RAP 9 cells, 7 animals). (E) Protein expression levels of NKA (NKA, CTL: n = 15; RAP: n = 11). (F) Protein expression levels of PLM and changes in PLM phosphorylation levels at Ser63 and Ser68 (CTL, PLM: n = 15, Ser63: n = 14, Ser68: n = 15; RAP, PLM: n = 7, Ser63: n = 7, Ser68: n = 6). *P 0.05.
Figure 4
Figure 4. Upregulation of NCX and unchanged SR Ca2+ content.
(A) Left panel: Original recordings of whole-cell CaTs (whole-cell epifluorescence, fluo-3) during caffeine application (10 mmol/l). Right panel: Caffeine-induced CaT amplitude (CTL: n = 22 cells, 5 animals; RAP: n = 16 cells, 5 animals). (B) SR Ca2+ content: Original recordings of INCX during caffeine application (10 mmol/l) and SR Ca2+ content based on integrated INCX (CTL: n = 18 cells, 4 animals; RAP: n = 16 cells, 5 animals). (C) Example of linear (slow) phase of INcx free [Ca2+]i plot obtained during simultaneous measurement of INCX and [Ca2+]i (whole-cell epifluorescence, fluo-3) during fast application of caffeine (10 mmol/l) in voltage-clamped atrial myocytes (CTL: n = 14 cells, 4 animals; RAP: n = 13 cells, 5 animals). (D) Left panels: Transverse confocal linescans during caffeine application depicting domain-specific SR Ca2+ load in a CTL cell and an RAP cell. (CTL: n = 15 cells, 4 animals; RAP: n = 13 cells, 4 animals). Right panel: Ratio of cc/ss caffeine-induced CaT amplitudes as an approximation of domain-specific SR Ca2+ content. **P 0.01.
Figure 3
Figure 3. Role of ICa,L reduction.
(A) Confocal linescan and derived local CaTs in a CTL myocyte before (left panel) and after (right panel) treatment with the Ca2+ channel antagonist nitrendipine (Nitr) (0.3 μmol/l). (B) Regional CaT amplitudes at baseline and after application of nitrendipine (n = 15 cells, 4 animals). (C) Averaged (n = 20) recordings of whole-cell CaT in CTL cells, CTL cells treated with nitrendipine, and RAP cells. (D) Whole-cell CaT amplitude, time to peak, and decay time (CTL and CTL plus nitrendipine: n = 14 cells, 4 animals; RAP: n = 22 cells, 5 animals). ***P 0.001.
Figure 2
Figure 2. Failure of centripetal Ca2+ wave propagation after RAP.
(A) Transverse confocal linescan and derived local CaTs from a CTL cell showing similar amplitudes of ss and cc CaTs. (B) Transverse confocal linescan and derived local CaTs from an RAP cell showing the significantly blunted cc CaT. (C) Reduced cc but preserved ss CaT amplitude in RAP cells at 2 Hz (CTL: n = 28 cells, 6 animals; RAP: n = 26 cells, 6 animals). ***P 0.001. F, fluorescence intensity; F0, baseline fluorescence intensity.
Figure 1
Figure 1. Contractile and electrical remodeling after RAP.
(A) Fractional myocyte shortening (CTL: n = 18 cells, 6 animals; RAP: n = 21 cells, 5 animals). (B) Cellular AP and APD at 2 Hz (CTL: n = 15 cells, 7 animals; RAP: n = 12 cells, 6 animals). (C) Left panel: Original recordings of ICa,L in a CTL and RAP cell. Right panel: Current-voltage relation (CTL: n = 19 cells, 6 animals; RAP: n = 17 cells, 5 animals).*P 0.05;**P 0.01; ***P 0.001.

Comment in

References

    1. Elvan A, et al. Dominant frequency of atrial fibrillation correlates poorly with atrial fibrillation cycle length. Circ Arrhythm Electrophysiol. 2009;2(6):634–644. doi: 10.1161/CIRCEP.108.843284. - DOI - PubMed
    1. Akar JG, et al. Intracellular chloride accumulation subcellular elemental distribution during atrial fibrillation. Circulation. 2003;107(13):1810–1815. doi: 10.1161/01.CIR.0000058462.23347.93. - DOI - PubMed
    1. Greiser M, Schotten U. Dynamic remodeling of intracellular Ca(2+) signaling during atrial fibrillation. J Mol Cell Cardiol. 2013;58:134–142. doi: 10.1016/j.yjmcc.2012.12.020. - DOI - PubMed
    1. Greiser M, Lederer WJ, Schotten U. Alterations of atrial Ca(2+) handling as cause consequence of atrial fibrillation. Cardiovasc Res. 2011;89(4):722–733. doi: 10.1093/cvr/cvq389. - DOI - PubMed
    1. Voigt N, et al. Enhanced sarcoplasmic reticulum Ca2+ leak increased Na+-Ca2+ exchanger function underlie delayed afterdepolarizations in patients with chronic atrial fibrillation. Circulation. 2012;125(17):2059–2070. doi: 10.1161/CIRCULATIONAHA.111.067306. - DOI - PMC - PubMed

Publication types

Substances